Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

Medically reviewed by Gagandeep Brar, MD Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually ...

They are generally classified according to the cancer's growth rate as high grade (fast growing ... of genetic subtypes in diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

– Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival ...

The following is a summary of “Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma,” published in the December 2024 issue of Hematology by ...

is the “first and only” T-cell engager for “relapsed or refractory DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B–cell lymphoma ...